Improving HIV vaccines to generate effective antibodies
Project 1. Optimization and in vivo evaluation of HIV-1 Env trimer sortase A-conjugated nanoparticles
This study is exploring a new way to create a vaccine that helps the immune system make strong antibodies against HIV-1, using tiny particles to present parts of the virus in a way that encourages the body to produce better defenses, and it's designed for people interested in improving HIV vaccine efforts.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project ID | NIH-11009914 on NIH RePORTER |
What this research studies
This research focuses on developing a new approach to create vaccines that can stimulate the immune system to produce broadly neutralizing antibodies (bnAbs) against HIV-1. It aims to enhance the affinity of these antibodies by using nanoparticles that present HIV-1 envelope proteins in a way that encourages the immune system to evolve high-affinity antibodies. The study will involve sequential immunizations to guide the immune response towards producing the desired antibodies, addressing challenges faced by previous vaccine attempts.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk for HIV infection who are interested in participating in innovative vaccine trials.
Not a fit: Patients who are already HIV-positive or those who have contraindications to vaccination may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more effective HIV vaccine that generates strong and lasting immune responses.
How similar studies have performed: Previous research has shown promise in using nanoparticle-based vaccine strategies to enhance antibody responses, indicating potential for success in this novel approach.
Where this research is happening
Durham, United States
- Duke University — Durham, United States (Active)
Researchers
- Principal investigator: Saunders, Kevin O — Duke University
- Study coordinator: Saunders, Kevin O
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.